RSS | Login | Register

VALCYTE for ORAL SOLUTION

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare VALCYTE for ORAL SOLUTION to:

Generic Name for VALCYTE for ORAL SOLUTION

Valganciclovir (as HCl) (prodrug of ganciclovir) 50mg/mL; pwd for reconstitution; tutti-frutti flavor.

Legal Classification:

Pharmacological Class for VALCYTE for ORAL SOLUTION

Nucleoside analogue.

Manufacturer of VALCYTE for ORAL SOLUTION

Roche Laboratories

Indications for VALCYTE for ORAL SOLUTION

Prevention of CMV disease in kidney and heart transplant pediatric patients (4 months to 16 years old) at high risk.

Adult dose for VALCYTE for ORAL SOLUTION

Use tablet form.

Children's dosing for VALCYTE for ORAL SOLUTION

<4months: not recommended. Take with food. ≥4months: Dose (mg)= 7 x BSA x Creatinine Clearance (see literature). Round calculated dose to the nearest 25mg increment; max 900mg.

Also:

VALCYTE

Contraindications for VALCYTE for ORAL SOLUTION

Acyclovir or ganciclovir allergy.

Warnings/Precautions for VALCYTE for ORAL SOLUTION

Do not substitute on a mg-per-mg basis for ganciclovir. Avoid handling broken tabs. Withhold dose if absolute neutrophil count <500 cells/microliter, platelet count <25,000/microliter, or hemoglobin <8 g/dL. Reduce dose or discontinue if blood dyscrasias occur. Renal impairment. Cytopenia or cytopenic reactions to drugs, chemicals, irradiation. Monitor CBCs, platelets, ophthalmic, and renal function. Maintain adequate hydration. Use effective contraception during (men and women) and for at least 90 days after treatment (men). Elderly. Pregnancy (Cat.C: teratogenic, embryotoxic, carcinogenic, aspermatogenesis in animals), nursing mothers: see literature.

Interactions for VALCYTE for ORAL SOLUTION

Zidovudine increases anemia/neutropenia risk. Caution with nephrotoxic drugs (eg, cyclosporine, amphotericin B, mycophenolate). Monitor for toxicity with didanosine. Probenecid increases levels. Caution with drugs that inhibit replication of rapidly-dividing cells (eg, dapsone, pentamidine, antineoplastics). Avoid imipenem-cilastatin (seizures).

Adverse Reactions for VALCYTE for ORAL SOLUTION

GI upset, fever, bone marrow depression, headache, insomnia, retinal detachment, peripheral neuropathy, paresthesia, aplastic anemia, bleeding, CNS effects, elevated serum creatinine, infections, tremor, hypertension.

How is VALCYTE for ORAL SOLUTION supplied?

Tabs—60
Soln—100mL (after constitution); available soon

Related Disease:

Cytomegalovirus

Abbott RealTime HBV test approved

September 02, 2010

Abbott announced that the FDA has approved its RealTime HBV assay for measuring the amount of hepatitis B virus (HBV) in human plasma or serum from individuals chronically infected with HBV.

Longer use of Valcyte for renal transplant patients approved

August 11, 2010

The FDA has approved a longer duration of therapy with Valcyte (valganciclovir, from Genentech) in adult renal transplant patients at high risk for cytomegalovirus (CMV) disease.

Phase 3 study of boceprevir for the treatment of HCV

August 05, 2010

Merck announced the completion and results of its two Phase 3 studies for boceprevir for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection.

Afluria labeling updated to include fever and febrile seizure risk

August 02, 2010

The Prescribing Information for Afluria (trivalent, inactivated, "split virus" influenza vaccine [Types A and B], from CSL Biotherapies) has been updated to inform healthcare professionals of an increased incidence of fever and febrile seizure among young children in Australia, mainly those <5years of age.

Fluzone available for 2010-2011 influenza season

July 30, 2010

Sanofi Pasteur announced that it has begun shipping the 2010-2011 formulation of Fluzone (trivalent inactivated "split virus" influenza vaccine [Types A and B]).